Hidetaka Akita

Prof. Dr. Hidetaka Akita

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2020 in Advanced Functional Materials
Verified
Journal Article
Open access
PDF file
HTHiroki Tanaka
Hiroki Tanaka
TTTatsunari Takahashi
Tatsunari Takahashi
MKManami Konishi
Manami Konishi
NTNae Takata
Nae Takata
MGMasaki Gomi
Masaki Gomi
HAHidetaka Akita
Hidetaka Akita
RNA‐based therapeutics is a promising approach for curing intractable diseases by manipulating various cellular functions. For eliciting RNA (i.e., mRNA and siRNA) functions successfully, the RNA in the extracellular space must be protected and it must be delivered to the cytoplasm. In this study, the development of a self‐degradable lipid‐like material that functions to accelerate the collapse of lipid nanoparticles (LNPs) and the release of RNA into cytoplasm is reported. The self‐degradability is based on a unique reaction “Hydrolysis accelerated by intra‐Particle Enrichment of Reactant (HyPER).” In this reaction, a disulfide bond and a phenyl ester are essential structural components: concentrated hydrophobic thiols that are produced by the cleavage of the disulfide bonds in the LNPs drive an intraparticle nucleophilic attack to the phenyl ester linker, which results in further degradation. An oleic acid‐scaffold lipid‐like material that mounts all of these units (ssPalmO‐Phe) shows superior transfection efficiency to nondegradable or conventional materials. The insertion of the aromatic ring is unexpectedly revealed to contribute to the enhancement of endosomal escape. Since the intracellular trafficking is a sequential process that includes cellular uptake, endosomal escape, the release of mRNA, and translation, the improvement in each process synergistically enhances the gene expression.

1 September 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
NTNaho Tateshita
Naho Tateshita
NMNaoya Miura
Naoya Miura
HTHiroki Tanaka
Hiroki Tanaka
TMTakeshi Masuda
Takeshi Masuda
SOSumio Ohtsuki
Sumio Ohtsuki
HAHidetaka Akita
Hidetaka Akita

1 August 2013 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
HAHidetaka Akita
Hidetaka Akita
RIRyohei Ishiba
Ryohei Ishiba
Hiroto HatakeyamaHiroto Hatakeyama
Hiroto Hatakeyama
HTHiroki Tanaka
Hiroki Tanaka
YSYusuke Sato
Yusuke Sato
HHHideyoshi Harashima
Hideyoshi Harashima

11 April 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
HTHiroki Tanaka
Hiroki Tanaka
TNTaichi Nakatani
Taichi Nakatani
TFTomomi Furihata
Tomomi Furihata
KTKota Tange
Kota Tange
YNYuta Nakai
Yuta Nakai
HAHidetaka Akita
Hidetaka Akita

1 February 2015 in Journal of Controlled Release
Verified
Journal Article
Open access
HAHidetaka Akita
Hidetaka Akita
RIRyohei Ishiba
Ryohei Ishiba
RTRyohei Togashi
Ryohei Togashi
KTKota Tange
Kota Tange
YNYuta Nakai
Yuta Nakai
HHHideyoshi Harashima
Hideyoshi Harashima
A renal cell carcinoma (RCC) is one of the refractory tumors, since it readily acquires resistance against chemotherapy. Thus, alternative therapeutic approaches such as obstructing the neovasculature are needed. We previously reported on the development of a plasmid DNA (pDNA)-encapsulating liposomal nanoparticle (LNP) as a hepatic gene delivery system that is applicable to systemic administration. The key molecular component is a SS-cleavable and pH-activated lipid-like material (ssPalm) that mounts dual sensing motifs (ternary amines and disulfide bonding) that are responsive to the intracellular environment. The main purpose of the present study was to expand its application to a tumor-targeting gene delivery system in mice bearing tumors established from a RCC (OS-RC-2). When the modification of the surface of the particle is optimized for the polyethyleneglycol (PEG), stability in the blood circulation is improved, and consequently tumor-selective gene expression can be achieved. Furthermore, gene expression in the tumor was increased slightly when the hydrophobic scaffold of the ssPalm was replaced from the conventionally used myristic acid (ssPalmM) to α-tocopherol succinate (ssPalmE). Moreover, tumor growth was significantly suppressed when the completely CpG-free pDNA encoding the solute form of VEGFR (fms-like tyrosine kinase-1: sFlt-1) was used, especially when it was delivered by the LNP formed with ssPalmE (LNP(ssPalmE)). Thus, the PEG-modified LNP(ssPalmE) is a promising gene carrier for the cancer gene therapy of RCC.

25 December 2022 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
MGMasaki Gomi
Masaki Gomi
YSYu Sakurai
Yu Sakurai
MSMinami Sato
Minami Sato
HTHiroki Tanaka
Hiroki Tanaka
YMYumi Miyatake
Yumi Miyatake
HAHidetaka Akita
Hidetaka Akita